Mental Health Survival Kit: References

This page contains the full list of footnotes for the book Mental Health Survival Kit and Withdrawal from Psychiatric Drugs by Peter Gøtzsche, which is being serialized on Mad in America. The chapters are available to read here, with a new chapter becoming available every Monday.

References

Chapter 1. This book might save your life

1. Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press;
   2015.
2. Jorm AF, Korten AE, Jacomb PA, et al. ”Mental health literacy”: a survey of the
   public’s ability to recognise mental disorders and their beliefs about the
   effectiveness of treatment. Med J Aus 1997;166:182-6.
3. Priest RG, Vize C, Roberts A, et al. Lay people’s attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its
   launch. BMJ 1996;313:858-9.
4. Paykel ES, Hart D, Priest RG. Changes in public attitudes to depression during the
   Defeat Depression Campaign. Br J Psychiatry 1998;173:519-22.
5. Read J, Timimi S, Bracken P, Brown M, Gøtzsche P, Gordon P, et al. Why did
   official accounts of antidepressant withdrawal symptoms differ so much from
   research findings and patients’ experiences? Ethical Hum Psychol Psychiatry
   (submitted).
6. Kessing L, Hansen HV, Demyttenaere K, et al. Depressive and bipolar disorders:
   patients’ attitudes and beliefs towards depression and antidepressants. Psychological Medicine 2005;35:1205-13.
7. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference
   for psychological vs pharmacologic treatment of psychiatric disorders: a metaana-lytic review. J Clin Psychiatry 2013;74:595-602.
8. Olfson M, Blanco C, Marcus SC. Treatment of adult depression in the United
   States. JAMA Intern Med 2016;176:1482-91.
9. Breggin P. The most dangerous thing you will ever do. Mad in America 2020;
   March 2. https://www.madinamerica.com/2020/03/dangerous-thing-psychiatrist/.
10. Gøtzsche PC. Psychiatry gone astray. 2014; Jan 21. https://davidhealy.org/psychiatry-gone-astray/.
11. Breggin PR. Brain-disabling treatments in psychiatry: drugs, electroshock, and the
    psychopharmaceutical complex. New York: Springer; 2008.
12. Breggin PR. Intoxication anosognosia: the spellbinding effect of psychiatric drugs.
    Ethical Hum Psychol Psychiatry 2006;8:201-15.
13. Gøtzsche P. Surviving psychiatry: a typical case of serious psychiatric drug harms.
    Mad in America 2020; Jan 7. https://www.madinamerica.com/2020/01/
    surviving-psychiatry-typical-case-serious-psychiatric-drug-harms/.
14. Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence
    on antidepressants: systematic review of trials in adult healthy volunteers. J R
    Soc Med 2016;109:381-92.
15. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine
    for treatment of stress urinary incontinence: a meta-analysis of clinical study
    reports. CMAJ 2017;189:E194-203.
16. Hengartner MP, Plöderl M. Newer-generation antidepressants and suicide risk in
    randomized controlled trials: a re-analysis of the FDA database. Psychother
    Psychosom 2019;88:247-8.
17. Hengartner MP, Plöderl M. Reply to the Letter to the Editor: “Newer-Generation
    Antidepressants and Suicide Risk: Thoughts on Hengartner and Plöderl’s ReAnalysis.” Psychother Psychosom 2019;88:373-4.
18. FDA package insert for Effexor. Accessed 4 Jan 2020.
    https://www.accessdata.fda. gov/drugsatfda_docs/label/2008/020151s051lbl.pdf.
19. FDA package insert for Neurontin. Accessed 4 Jan 2020. https://www.accessdata.
    fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.p
    df
20. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal
    symptoms. Lancet Psychiatry 2019;6:538-46.
21. Davidsen AS, Jürgens G, Nielsen RE. Farmakologisk behandling af unipolar depression hos voksne i almen praksis. Rationel Farmakoterapi 2019; Nov.
22. Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself.
    Copenhagen: People’s Press; 2019.
23. Demasi M, Gøtzsche PC. Presentation of benefits and harms of antidepressants on
    websites: cross sectional study. Int J Risk Saf Med 2020;31:53-65.
24. Whitaker R. Anatomy of an epidemic, 2nd edition. New York: Broadway Paperbacks; 2015.

Chapter 2. Is psychiatry evidence-based?

1. Whitaker R. Mad in America: bad science, bad medicine, and the enduring mistreatment of the mentally ill. Cambridge: Perseus Books Group; 2002.
2. Healy D. Let them eat Prozac. New York: New York University Press; 2004.
3. Whitaker R. Anatomy of an epidemic, 2nd edition. New York: Broadway Paperbacks; 2015.
4. Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press;
   2015.
5. Medawar C. The antidepressant web – marketing depression and making medicines
   work. Int J Risk & Saf Med 1997;10:75-126.
6. Caplan PJ. They say you’re crazy: how the world’s most powerful psychiatrists
   decide who’s normal. Jackson: Da Capo Press; 1995.
7. Breggin PR. Brain-disabling treatments in psychiatry: drugs, electroshock, and the
   psychopharmaceutical complex. New York: Springer; 2008.
8. Kirsch I. The Emperor’s new drugs: exploding the antidepressant myth. New York:
   Basic Books; 2009.
9. Moncrieff J. The bitterest pills. Basingstoke: Palgrave Macmillan; 2013.
10. Davies J, ed. The sedated society. London: Palgrave Macmillan; 2017.
11. McLaren N. Anxiety, the inside story. How biological psychiatry got it wrong.
    Ann Arbor: Future Psychiatry Press; 2018.
12. Sharfstein S. Big Pharma and American psychiatry: The good, the bad and the
    ugly. Psychiatric News 2005;40:3.
13. Angermeyer MC, Holzinger A, Carta MG, et al. Biogenetic explanations and
    public acceptance of mental illness: systematic review of population studies. Br J
    Psychiatry 2011;199:367–72.
14. Read J, Haslam N, Magliano L. Prejudice, stigma and “schizophrenia:” the role of
    bio-genetic ideology. In: Models of Madness. (John Read and JacquiDillon,
    eds.). London: Routledge, 2013.
15. Read J, Haslam N, Sayce L, et al. Prejudice and schizophrenia: a review of the
    “mental illness is an illness like any other” approach. Acta Psychiatr Scand
    2006;114:303-18.
16. Kvaale EP, Haslam N, Gottdiener WH. The ‘side effects’ of medicalization: a
    meta-analytic review of how biogenetic explanations affect stigma. Clin Psychol
    Rev 2013;33:782–94.
17. Lebowitz MS, Ahn WK. Effects of biological explanations for mental disorders on
    clinicians’ empathy. Proc Natl Acad Sci USA 2014;111:17786-90.
18. Davies J. Cracked: why psychiatry is doing more harm than good. London: Icon
    Books; 2013.
19. Kirk SA, Kutchins H. The selling of DSM: the rhetoric of science in psychiatry.
    New York: Aldine de Gruyter; 1992.
20. Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for
    DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry
    1992;49:630-6.
21. Adult ADHD Self-Report Scale-V1.1 (ASRS-V1.1) Symptoms Checklist from
    WHO Composite International Diagnostic Interview; 2003.
22. Pedersen AT. En psykiatrisk diagnose hænger ved resten af livet. PsykiatriAvisen
    2019; Jan 18. https://www.psykiatriavisen.dk/2019/01/18/en-psykiatriskdiagnose-haenger-ved-resten-af-livet/.
23. Frandsen P. Et anker af flamingo: Det, vi glemmer, gemmer vi i hjertet. Odense:
    Mellemgaard; 2019.
24. Pedersen AT. Diagnosing Psychiatry.
    https://vimeo.com/ondemand/diagnosingpsychiatryen.
25. Breggin P. The most dangerous thing you will ever do. Mad in America 2020;
    March 2. https://www.madinamerica.com/2020/03/dangerous-thing-psychiatrist/.
    190
26. Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and
    juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc
    Psychiatry 1996;35:997-1008.
27. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National trends in
    the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen
    Psychiatry 2007;64:1032-9.
28. Gøtzsche PC. Psychopharmacology is not evidence-based medicine. In: James D
    (ed.). The sedated society. The causes and harms of our psychiatric drug
    epidemic. London: Palgrave Macmillan; 2017.
29. Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W, et al.
    Childhood adversities increase the risk of psychosis: a meta-analysis of patientcontrol, prospective- and cross-sectional cohort studies. Schizophr Bull
    2012;38:661-71.
30. Shevlin M, Houston JE, Dorahy MJ, Adamson G. Cumulative traumas and
    psychosis: an analysis of the national comorbidity survey and the British
    Psychiatric Morbidity Survey. Schizophr Bull 2008;34:193-9.
31. Kingdon D, Sharma T, Hart D and the Schizophrenia Subgroup of the Royal
    College of Psychiatrists’ Changing Mind Campaign. What attitudes do
    psychiatrists hold towards people with mental illness? Psychiatric Bulletin
    2004;28:401-6.
32. Demasi M, Gøtzsche PC. Presentation of benefits and harms of antidepressants on
    websites: cross sectional study. Int J Risk Saf Med 2020;31:53-65.
33. Kessing L, Hansen HV, Demyttenaere K, et al. Depressive and bipolar disorders:
    patients’ attitudes and beliefs towards depression and antidepressants. Psychological Medicine 2005;35:1205-13.
34. Christensen AS. DR2 undersøger Danmark på piller. 2013; Mar 20.
    https://www.dr.dk/presse/dr2-undersoeger-danmark-paa-piller.
35. Ditzel EE. Psykiatri-professor om DR-historier: ”Skræmmekampagne der kan
    koste liv.” Journalisten 2013; Apr 11. https://journalisten.dk/psykiatri-professorom-dr-historier-skraemmekampagne-der-kan-koste-liv/.
36. Gøtzsche PC. Death of a whistleblower and Cochrane’s moral collapse. Copenhagen: People’s Press; 2019.
37. Sterll B. Den psykiatriske epidemi. Psykolognyt 2013;20:8-11.
38. Gøtzsche PC. Psychiatry gone astray. 2014; Jan 21. https://davidhealy.org/psychiatry-gone-astray/.
39. Rasmussen LI. Industriens markedsføring er meget, meget effektiv. Den har fået
    lægerne til at tro på, at eksempelvis antidepressiva er effektive lægemidler. Det
    er de overhovedet ikke. Politiken 2015; Aug 30:PS 8-9.
40. Schultz J. Peter Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin
    2015; Oct 2. http://www.dagensmedicin.dk/nyheder/psykiatri/gotzsche-melderpsykiater-til-lageetisk-navn/.
41. Psykiatrifonden. Depression er en folkesygdom – især for kvinder. 2017; Jan 31.
    http://www.psykiatrifonden.dk/viden/gode-raad-ogtemaer/depression/depression-er-en-folkesygdom.aspx.
42. Kessing LV. Depression, hvordan virker medicin. Patienthåndbogen 2015; July 5.
    https://www.sundhed.dk/borger/patienthaandbogen/psyke/sygdomme/laegemidle
    r/depression-hvordan-virker-medicin/.
43. Videbech P. SSRI, antidepressivum. Patienthåndbogen 2015; July 23.
    https://www.sundhed.dk/borger/patienthaandbogen/psyke/sygdomme/laegemidle
    r/ssri-antidepressivum/.
44. Scheuer SR. Studerende: Antidepressiv medicin er ikke løsningen på sjælelige
    problemer. Kristeligt Dagblad 2018; Mar 19.
45. Christensen DC. Dear Luise: a story of power and powerlessness in Denmark’s
    psychiatric care system. Portland: Jorvik Press; 2012.
46. Angoa-Pérez M, Kane MJ, Briggs DI. et al. Mice genetically depleted of brain
    serotonin do not display a depression-like behavioral phenotype. ACS Chem
    Neurosci 2014;5:908-19.
47. Hindmarch I. Expanding the horizons of depression: beyond the monoamine
    hypothesis. Hum Psychopharmacol 2001;16:203-218.
48. Castrén E. Is mood chemistry? Nat Rev Neurosci 2005;6:241-6.
49. Gøtzsche PC, Dinnage O. What have antidepressants been tested for? A
    systematic review. Int J Risk Saf Med 2020;31:157-63.
50. Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding
    psychotropic drug action. Am J Psychiatry 1996;153:151-62.
51. Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013.
52. Moncrieff J, Cohen D. Do antidepressants cure or create abnormal brain states?
    PLoS Med 2006;3:e240.
53. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat
    1960;23:56-62.
54. Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself.
    Copenhagen: People’s Press; 2019.
55. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during
    antidepressant treatment: systematic review and meta-analyses based on clinical
    study reports. BMJ 2016;352:i65.
56. Breggin P. Psychiatric drug withdrawal: A guide for prescribers, therapists,
    patients and their families. New York: Springer; 2012.
57. Davies J, Read J. A systematic review into the incidence, severity and duration of
    antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav
    2019;97:111-21.
58. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drugnaïve patients with psychosis: A systematic review. Int J Risk Saf Med
    2019;30:193-201.
59. Francey SM, O’Donoghue B, Nelson B, Graham J, Baldwin L, Yuen HP, et al.
    Psychosocial intervention with or without antipsychotic medication for first
    episode psychosis: a randomized noninferiority clinical trial. Schizophr Bull
    Open 2020; Mar 20. https://doi.org/10.1093/schizbullopen/sgaa015.
60. Bola J, Kao D, Soydan H, et al. Antipsychotic medication for early episode
    schizophrenia. Cochrane Database Syst Rev 2011;6:CD006374.
61. Demasi M. Cochrane – A sinking ship? BMJ 2018; 16 Sept.https://blogs.bmj.com/
    bmjebmspotlight/2018/09/16/cochrane-a-sinking-ship/.
62. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for
    relapse prevention in schizophrenia: a systematic review and meta-analysis.
    Lancet 2012;379:2063-71.
63. Wunderink L, Nieboer RM, Wiersma D, et al. Recovery in remitted first-episode
    psychosis at 7 years of follow-up of an early dose reduction/discontinuation or
    maintenance treatment strategy: long-term follow-up of a 2-year randomized
    clinical trial. JAMA Psychiatry 2013;70:913-20.
64. Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, et al.
    Long-term effects of discontinuation from antipsychotic maintenance following
    first-episode schizophrenia and related disorders: a 10 year follow-up of a
    randomised, double-blind trial. Lancet Psychiatry 2018;5:432-42.
65. Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. Maintenance
    treatment with quetiapine versus discontinuation after one year of treatment in
    patients with remitted first episode psychosis: randomised controlled trial. BMJ
    2010;341:c4024.
66. Whitaker R. Lure of riches fuels testing. Boston Globe 1998; Nov 17.
67. Cole JO. Phenothiazine treatment in acute schizophrenia; effectiveness: the
    National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Arch Gen Psychiatry 1964;10:246-61.
68. Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical
    implications. Neuropsychopharmacology 2006;31:2318-25.
69. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from
    schizophrenia trials in support of new drug applications submitted to the US
    Food and Drug Administration. J Clin Psychiatry 2012;73:856–64.
70. Leucht S, Fennema H, Engel R, et al. What does the HAMD mean? J Affect
    Disord 2013;148:243-8.
71. Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors
    versus placebo in patients with major depressive disorder. A systematic review
    with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017;17:58.
72. Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al.
    Comparative efficacy and tolerability of antidepressants for major depressive
    disorder in children and adolescents: a network meta-analysis. Lancet
    2016;388:881-90.
73. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant
    benefits: A meta-analysis of data submitted to the Food and Drug
    Administration. PLoS Med 2008;5:e45.
74. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and
    depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
75. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of
    repeated suicide attempts: systematic review. J R Soc Med 2017;110:404-10.
76. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for
    depression. Cochrane Database Syst Rev 2004;1:CD003012.
77. Moncrieff J. The myth of the chemical cure. Basingstoke: Palgrave Macmillan;
    2008.
78. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin
    reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J
    Psychiatry 2000;176:363-8.
79. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biol Psychiatry 1998;44:77-
    87.
80. Breggin P. Medication madness. New York: St. Martin’s Griffin; 2008.
81. Hughes S, Cohen D, Jaggi R. Differences in reporting serious adverse events in
    industry sponsored clinical trial registries and journal articles on antidepressant
    and antipsychotic drugs: a cross-sectional study. BMJ Open 2014;4:e005535.
82. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic
    drug treatment for dementia: meta-analysis of randomized placebo-controlled
    trials. JAMA 2005;294:1934–43.
83. FDA. Alert for Healthcare Professionals: Risperidone (marketed as Risperdal).
    2006; Sept https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm. Link inactive, as the issue has
    been described in the risperidone package insert: https://www.accessdata.fda.
    gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s0
    3lbl.pdf.
84. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and
    life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet
    Psychiatry 2017;4:295-301.
85. Gøtzsche PC. Psychiatry ignores an elephant in the room. Mad in America 2017;
    Sept 21. https://www.madinamerica.com/2017/09/psychiatry-ignores-elephant-room.
86. Hegelstad WT, Larsen TK, Auestad B, et al. Long-term follow-up of the TIPS
    early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry
    2012;169:374-80.
87. Melle I, Olav Johannesen J, Haahr UH, et al. Causes and predictors of premature
    death in first-episode schizophrenia spectrum disorders. World Psychiatry
    2017;16:217-8.
88. Chung DT, Ryan CJ, Hadzi-Pavlovic D, et al. Suicide rates after discharge from
    psychiatric facilities: a systematic review and meta-analysis. JAMA Psychiatry
    2017;74:694-702.
89. Hjorthøj CR, Madsen T, Agerbo E et al. Risk of suicide according to level of
    psychiatric treatment: a nationwide nested case-control study. Soc Psychiatry
    Psychiatr Epidemiol 2014;49:1357–65.
90. Large MM, Ryan CJ. Disturbing findings about the risk of suicide and psychiatric
    hospitals. Soc Psychiatry Psychiatr Epidemiol 2014;49:1353–5.
91. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry
    1997;171:502-8.
92. Wils RS, Gotfredsen DR, Hjorthøj C, et al. Antipsychotic medication and
    remission of psychotic symptoms 10 years after a first-episode psychosis.
    Schizophr Res 2017;182:42-8.
93. Forskningsrådet. Tilgjengeliggjøring av forskningsdata. 2017; Dec. ISBN 978-82-
    12-03653-6.
94. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than
    good? BMJ 2015;350:h2435.
95. Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. Cochrane
    Database Syst Rev 2012;11:CD006391.
96. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse
    outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
97. Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence
    on antidepressants: systematic review of trials in adult healthy volunteers. J R
    Soc Med 2016;109:381-92.
98. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine
    for treatment of stress urinary incontinence: a meta-analysis of clinical study
    reports. CMAJ 2017;189:E194-203.
99. Hengartner MP, Plöderl M. Newer-generation antidepressants and suicide risk in
    randomized controlled trials: a re-analysis of the FDA database. Psychother
    Psychosom 2019;88:247-8.
100. Hengartner MP, Plöderl M. Reply to the Letter to the Editor: “Newer-Generation
     Antidepressants and Suicide Risk: Thoughts on Hengartner and Plöderl’s ReAnalysis.” Psychother Psychosom 2019;88:373-4.
     195
101. Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude
     E. Restoring Study 329: efficacy and harms of paroxetine and imipramine in
     treatment of major depression in adolescence. BMJ 2015;351:h4320.
102. Lars Kessing i Aftenshowet. DR1 2013; Apr 15.
103. Klein DF. The flawed basis for FDA post-marketing safety decisions: the
     example of anti-depressants and children. Neuropsychopharmacology
     2006;31:689–99.
104. Emslie GJ, Rush AJ, Weinberg WA, et al. Rintelmann J. A double-blind,
     randomized, placebo-controlled trial of fluoxetine in children and adolescents
     with depression. Arch Gen Psychiatry 1997;54:1031-7.
105. Eli Lilly and Company. Protocol B1Y-MC-X065. Clinical study main report:
     Fluoxetine versus placebo in the acute treatment of major depressive disorder in
     children and adolescents. 2000; Aug 8.
106. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL.
     Efficacy and safety of antidepressants for children and adolescents. BMJ
     2004;328:879-83.
107. Laughren TP. Overview for December 13 Meeting of Psychopharmacologic
     Drugs Advisory Committee (PDAC). 2006; Nov 16.
     www.fda.gov/ohrms/dockets/ac/06/ briefing/2006-4272b1-01-FDA.pdf.
108. Vanderburg DG, Batzar E, Fogel I, et al. A pooled analysis of suicidality in
     double-blind, placebo-controlled studies of sertraline in adults. J Clin Psychiatry
     2009;70:674-83.
109. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs)
     and suicide in adults: meta-analysis of drug company data from placebo
     controlled, randomised controlled trials submitted to the MHRA’s safety review.
     BMJ 2005;330:385.
110. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts
     and selective serotonin reuptake inhibitors: systematic review of randomised
     controlled trials. BMJ 2005;330:396.
111. FDA. Antidepressant use in children, adolescents, and adults. http://www.fda.
     gov/drugs/drugsafety/informationbydrugclass/ucm096273.htm.
112. Australian Government, Department of Health. The mental health of Australians.
     2009 May. https://www1.health.gov.au/internet/publications/publishing.nsf/Content/mental-pubs-m-mhaust2-toc~mental-pubs-m-mhaust2-hig~mental-pubs-mmhaust2-hig-sui.
113. Crowner ML, Douyon R, Convit A, Gaztanaga P, Volavka J, Bakall R. Akathisia
     and violence. Psychopharmacol Bull 1990;26:115-7.
114.  Sharma T, Guski LS, Freund N, Meng DM, Gøtzsche PC. Drop-out rates in
     placebo-controlled trials of antidepressant drugs: A systematic review and metaanalysis based on clinical study reports. Int J Risk Saf Med 2019;30:217-32.
     196
115. Paludan-Müller AS, Sharma T, Rasmussen K, Gøtzsche PC. Extensive selective
     reporting of quality of life in clinical study reports and publications of placebocontrolled trials of antidepressants. Int J Risk Saf Med 2020 (in press).
116. Montejo A, Llorca G, Izquierdo J, et al. Incidence of sexual dysfunction
     associated with antidepressant agents: a prospective multicenter study of 1022
     outpatients. Spanish Working Group for the study of psychotropic-related sexual
     dysfunction. J Clin Psychiatry 2001;62 (suppl 3):10–21.
117. Healy D, Le Noury J, Mangin D. Enduring sexual dysfunction after treatment
     with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J
     Risk Saf Med 2018;29:125-34.
118. Healy D, Le Noury J, Mangin D. Post-SSRI sexual dysfunction: Patient experiences of engagement with healthcare professionals. Int J Risk Saf Med
     2019;30:167-78.
119. Healy D. Antidepressants and sexual dysfunction: a history. J R Soc Med
     2020;113:133-5.
120. FDA package insert for Prozac. Accessed 14 March 2020. https://pi.lilly.com/
     us/prozac.pdf.
121. Medawar C, Hardon A. Medicines out of Control? Antidepressants and the
     conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.
122. FDA package insert for Effexor. Accessed 4 Jan 2020. https://www.accessdata.
     fda.gov/drugsatfda_docs/label/2008/020151s051lbl.pdf.
123. FDA package insert for Lithobid. Accessed 12 March 2020. https://www.
     accessdata.fda.gov/drugsatfda_docs/label/2016/018027s059lbl.pdf.
124. Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in
     mood disorders: updated systematic review and meta-analysis. BMJ
     2013;346:f3646.
125. Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood
     disorders: A systematic review. Int J Risk Saf Med 2019;30:155-66.
126. FDA package insert for Neurontin. Accessed 4 Jan 2020. https://www.
     accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_02112
     9s046lbl.pdf.
127. Ghaemi SN. The failure to know what isn’t known: negative publication bias
     with lamotrigine and a glimpse inside peer review. Evid Based Ment Health
     2009;12:65-8.
128. Weingart SN, Wilson RM, Gibberd RW, et al. Epidemiology of medical error.
     BMJ 2000;320:774–7.
129. Starfield B. Is US health really the best in the world? JAMA 2000;284:483–5.
130. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in
     hospitalized patients: a meta-analysis of prospective studies. JAMA
     1998;279:1200–5.
131. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of
     internal medicine. Arch Intern Med 2001;161:2317–23.
132. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9.
133. van der Hooft CS, Sturkenboom MC, van Grootheest K, et al. Adverse drug
     reaction-related hospitalisations: a nationwide study in The Netherlands. Drug
     Saf 2006;29:161-8.
134. Landrigan CP, Parry GJ, Bones CB, et al. Temporal trends in rates of patient
     harm resulting from medical care. N Engl J Med 2010;363:2124-34.
135. James JTA. A new, evidence-based estimate of patient harms associated with
     hospital care. J Patient Saf 2013;9:122-8.
136. Archibald K, Coleman R, Foster C. Open letter to UK Prime Minister David
     Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet
     2011;377:1915.
137. Makary MA, Daniel M. Medical error – the third leading cause of death in the
     US. BMJ 2016;353:i2139.
138. Centers for Disease Control and Prevention. Leading causes of death. www.cdc.
     gov/nchs/fastats/lcod.htm.
139. WHO. Management of substance abuse. Amphetamine-like substances. Undated.
     Downloaded 14 March 2020. https://www.who.int/substance_abuse/facts/
     ATS/en/.
140. National Institute on Drug Abuse. What is the scope of methamphetamine misuse
     in the United States? 2019; Oct. https://www.drugabuse.gov/publications/
     research-reports/methamphetamine/what-scope-methamphetamine-misuse-inunited-states.
141. Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports
     of violence towards others. PLoS One 2010;5:e15337.
142. Molina BS, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J
     Am Acad Child Adolesc Psychiatry 2007;46:1028-40.
143. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment
     strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry
     1999;56:1073-86.
144. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA
     study. J Am Acad Child Adolesc Psychiatry 2007;46:989-1002.
145. Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective
     follow-up of children treated for combined-type ADHD in a multisite study. J
     Am Acad Child Adolesc Psychiatry 2009;48:484-500.
146. Swanson JM, Arnold LE, Molina BSG, et al. Young adult outcomes in the
     follow-up of the multimodal treatment study of attention-deficit/hyperactivity
     disorder: symptom persistence, source discrepancy, and height suppression. J
     Child Psychol Psychiatry 2017;58:663-78.
147. Borcherding BG, Keysor CS, Rapoport JL, et al. Motor/vocal tics and
     compulsive behaviors on stimulant drugs: is there a common vulnerability?
     Psychiatry Res 1990;33:83-94.
148. Breggin PR. The rights af children and parents in regard to children receiving
     psychiatric diagnoses and drugs. Children & Society 2014;28:231-41.
149. Danborg PB, Simonsen AL, Gøtzsche PC. Impaired reproduction after exposure
     to ADHD drugs: Systematic review of animal studies. Int J Risk Saf Med
     2017;29:107-24.
150. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year
     review. Can J Psychiatry 1999;44:811-3.
151. Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC, et al. The
     Cochrane Collaboration withdraws a review on methylphenidate for adults with
     attention deficit hyperactivity disorder. Evid Based Med 2017;22:143-7.
152. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al.
     Methylphenidate for children and adolescents with attention deficit hyperactivity
     disorder (ADHD). Cochrane Database Syst Rev 2015;11:CD009885.
153. Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ. Extended-release
     methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
     Cochrane Database Syst Rev 2017;11:CD012857 (protocol; review in progress).
154. Wallach-Kildemoes H, Skovgaard AM, Thielen K, Pottegård A, Mortensen LH.
     Social adversity and regional differences in prescribing of ADHD medication for
     school-age children. J Dev Behav Pediatr 2015;36:330-41.
155. RL, Garland EJ, Wright JM, et al. Influence of relative age on diagnosis and
     treatment of attention-deficit/hyperactivity disorder in children. CMAJ
     2012;184:755-62.
156. Santaguida P, MacQueen G, Keshavarz H, Levine M, Beyene J, Raina P.
     Treatment for depression after unsatisfactory response to SSRIs. Comparative
     effectiveness review No. 62. (Prepared by McMaster University Evidence-based
     Practice Center under Contract No. HHSA 290 2007 10060 I.) AHRQ
     Publication No.12-EHC050-EF. Rockville, MD: Agency for Healthcare
     Research and Quality; 2012: April. www.ahrq.gov/clinic/epcix.htm.
157. Rink L, Braun C, Bschor T, Henssler J, Franklin J, Baethge C. Dose increase
     versus unchanged continuation of antidepressants after initial antidepressant
     treatment failure in patients with major depressive disorder: a systematic review
     and meta-analysis of randomized, double-blind trials. J Clin Psychiatry
     2018;79(3).
158. Samara MT, Klupp E, Helfer B, Rothe PH, Schneider-Thoma J, Leucht S.
     Increasing antipsychotic dose for non response in schizophrenia. Cochrane
     Database Syst Rev 2018;5:CD011883.
159. Miller M, Swanson SA, Azrael D, Pate V, Stürmer T. Antidepressant dose, age,
     and the risk of deliberate self-harm. JAMA Intern Med 2014;174:899-909.
160. Ho BC, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and
     brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen
     Psychiatry 2011;68:128-37.
161. Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive
     brain disease. Schizophr Bull 2013;39:1363-72.
162. Videbech P. Debatten om antidepressiv medicin – Virker det, og bliver man
     afhængig? BestPractice Psykiatri/Neurologi 2014; May:nr. 25.
163. Ownby RL, Crocco E, Acevedo A, et al. Depression and risk for Alzheimer
     disease: systematic review, meta-analysis, and metaregression analysis. Arch
     Gen Psychiatry 2006;63:530-8.
164. Moraros J, Nwankwo C, Patten SB, Mousseau DD. The association of
     antidepressant drug usage with cognitive impairment or dementia, including
     Alzheimer disease: A systematic review and meta-analysis. Depress Anxiety
     2017;34:217-26.
165.  Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J.
     Anticholinergic drug exposure and the risk of dementia: a nested case-control
     study. JAMA Intern Med 2019; Jun 24.
166. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy
     in office-based psychiatry. Arch Gen Psychiatry 2010;67:26-36.
167. Videos from International meeting: Psychiatric drugs do more harm than good.
     Copenhagen 2015; Sept 16. https://www.deadlymedicines.dk/wpcontent/uploads/2014/10/International-meeting1.pdf
168. Gøtzsche PC. Long-term use of antipsychotics and antidepressants is not
     evidence-based. Int J Risk Saf Med 2020;31:37-42.
169. Belmaker RH, Wald D. Haloperidol in normals. Br J Psychiatry 1977;131:222-3.
170. Kroken RA, Kjelby E, Wentzel-Larsen T, Mellesdal LS, Jørgensen HA, Johnsen
     E. Time to discontinuation of antipsychotic drugs in a schizophrenia cohort:
     influence of current treatment strategies. Ther Adv Psychopharmacol
     2014;4:228-39.
171. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to
     benzodiazepines and selective serotonin reuptake inhibitors. How did the health
     authorities react? Int J Risk Saf Med 2013;25:155-68.
172. Committee on the Review of Medicines. Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam,
     clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Br Med J 1980;280:910-2.
173. Gøtzsche PC. Long-term use of benzodiazepines, stimulants and lithium is not
     evidence-based. Clin Neuropsychiatry 2020;17 (in press).
     200
174. Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental
     disorders in England, 1998-2010. Br J Psychiatry 2012;200:393-8.
175. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales
     of selective serotonin reuptake inhibitors are closely related to number of
     products. Int J Risk Saf Med 2011;23:125-32.
176. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between
     dependence and withdrawal reactions? A comparison of benzodiazepines and
     selective serotonin re-uptake inhibitors. Addict 2012;107:900-8.
177. Oswald I, Lewis SA, Dunleavy DL, Brezinova V, Briggs M. Drugs of
     dependence though not of abuse: fenfluramine and imipramine. Br Med J
     1971;3:70-3.
178. Priest RG, Vize C, Roberts A, et al. Lay people’s attitudes to treatment of
     depression: results of opinion poll for Defeat Depression Campaign just before
     its launch. BMJ 1996;313:858-9.
179. Read J, Timimi S, Bracken P, Brown M, Gøtzsche P, Gordon P, et al. Why did
     official accounts of antidepressant withdrawal symptoms differ so much from
     research findings and patients’ experiences? Ethical Hum Psychol Psychiatry
     (submitted).
180. Public Health England. Dependence and withdrawal associated with some prescribed medications: an evidence Review. 2019; Sept. https://assets.publishing.
     service.gov.uk/government/uploads/system/uploads/attachment_data/file/829777
     /PHE_PMR_report.pdf.
181. Nutt DJ, Goodwin GM, Bhugra D, Fazel S, Lawrie S. Attacks on antidepressants: signs of deep-seated stigma? Lancet Psychiatry 2014;1:102-4.
182. Raven M. Depression and antidepressants in Australia and beyond: a critical
     public health analysis (PhD thesis). University of Wollongong, Australia; 2012.
     http://ro.uow.edu.au/theses/3686/.
183. Gøtzsche PC. Usage of depression pills almost halved among children in
     Denmark. Mad in America 2018; May 4.
     https://www.madinamerica.com/2018/05/usage-depression-pills-almost-halvedamong-children-denmark/.
184. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical
     evidence for selective reporting of outcomes in randomized trials: comparison of
     protocols to published articles. JAMA 2004;291:2457-65.
185. Carney S, Geddes J. Electroconvulsive therapy. BMJ 2003;326:1343-4.
186. Read J, Bentall R. The effectiveness of electroconvulsive therapy: a literature
     review. Epidemiol Psichiatr Soc 2010 Oct-Dec;19:333-47.
187. Rose D, Fleischmann P, Wykes T, et al. Patients’ perspectives on electroconvulsive therapy: systematic review. BMJ 2003;326:1363.

Chapter 3. Psychotherapy

1. Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press;
   2015.
2. Gøtzsche PC. Chemical or psychological psychotherapy? Mad in America 2017;
   Jan 29. https://www.madinamerica.com/2017/01/chemical-psychologicalpsychotherapy/.
3. Krupnick JL, Sotsky SM, Simmens S, et al. The role of the therapeutic alliance in
   psychotherapy and pharmacotherapy outcome: Findings in the National Institute
   of Mental Health Treatment of Depression Collaborative Research Program. J
   Consult Clin Psychol 1996;64:532–9.
4. Demyttenaere K, Donneau A-F, Albert A, et al. What is important in being cured
   from: Does discordance between physicians and patients matter? (2). J Affect
   Disord 2015;174:372–7.
5. Sørensen A, Gøtzsche. Antidepressant drugs are a type of maladaptive emotion
   regulation (submitted).
6. Spielmans GI, Berman MI, Usitalo AN. Psychotherapy versus second-generation
   antidepressants in the treatment of depression: a meta-analysis. J Nerv Ment Dis
   2011;199:142–9.
7. Cuijpers P, Hollon SD, van Straten A, et al. Does cognitive behaviour therapy have
   an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open 2013;26;3(4).
8. Breggin PR. Intoxication anosognosia: the spellbinding effect of psychiatric drugs.
   Ethical Hum Psychol Psychiatry 2006;8:201–15.
9. Breggin PR. Brain-disabling treatments in psychiatry: drugs, electroshock, and the
   psychopharmaceutical complex. New York: Springer; 2008.
10. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of
    repeated suicide attempts: systematic review. J R Soc Med 2017;110:404-10.
11. Hawton K, Witt KG, Taylor Salisbury TL, et al. Psychosocial interventions for
    self-harm in adults. Cochrane Database Syst Rev 2016;5:CD012189.
12. Morrison AP, Turkington D, Pyle M, et al. Cognitive therapy for people with
    schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind
    randomised controlled trial. Lancet 2014;383:1395-403.
13. Seikkula J, AaltonenJ, Alakare B, et al. Five-year experience of first-episode
    nonaffective psychosis in open-dialogue approach: Treatment principles, followup outcomes, and two case studies. Psychotherapy Research 2006;16:214-28.
14. Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a
    total urban population: a 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol
    2001;36:332-7.
15. Harnisch H, Montgomery E. “What kept me going”: A qualitative study of
    avoidant responses to war-related adversity and perpetration of violence by
    202
    former forcibly recruited children and youth in the Acholi region of northern
    Uganda. Soc Sci Med 2017;188:100-8.
16. Nilsonne Å. Processen: möten, mediciner, beslut. Stockholm: Natur & Kultur;
    2017.

Chapter 4. Withdrawing from psychiatric drugs

1. Gøtzsche PC. Deadly medicines and organised crime: How big pharma has
   corrupted health care. London: Radcliffe Publishing; 2013.
2. BBC. “My anti-depressant withdrawal was worse than depression.” 2020 Mar 12.
   https://www.bbc.co.uk/programmes/p086fjk7.
3. Gøtzsche PC. Sundhedsstyrelsens råd om depressionspiller er farlige. Politikens
   Kronik 2010 Feb 6.
4. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal
   symptoms. Lancet Psychiatry 2019;6:538-46.
5. Gøtzsche PC. Prescription pills are Britain’s third biggest killer: Side-effects of
   drugs taken for insomnia and anxiety kill thousands. Why do doctors hand them
   out like Smarties? Daily Mail 2015; Sept 15. http://www.dailymail.co.uk/health/
   article-3234334/Prescription-pills-Britain-s-biggest-killer-effects-drugs-takeninsomnia-anxiety-kill-thousands-doctors-hand-like-Smarties.html.
6. Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press;
   2015.
7. Gøtzsche PC. Death of a whistleblower and Cochrane’s moral collapse. Copenhagen: People’s Press; 2019.
8. Public Health England. Dependence and withdrawal associated with some
   prescribed medications: an evidence Review. 2019; Sept. https://assets.
   publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/
   file/829777/PHE_PMR_report.pdf.
9. Guy A, Davies J, Rizq R (eds.) Guidance for psychological therapists: Enabling
   conversations with clients taking or withdrawing from prescribed psychiatric
   drugs. London: APPG for Prescribed Drug Dependence; 2019 Dec.
10. Ho BC, Andreasen NC, Ziebell S, et al. Long-term antipsychotic treatment and
    brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen
    Psychiatry 2011;68:128-37.
11.  Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive
    brain disease. Schizophr Bull 2013;39:1363-72.
12. Timimi S. Death of a whistleblower and Cochrane’s moral collapse. Psychosis
    2019; Oct 30. https://doi.org/10.1080/17522439.2019.1685584.
13. Gøtzsche PC, Sørensen A. The review on antidepressant withdrawal that Cochrane
    won’t publish. Mad in America 2020; Feb 11. https://www.madinamerica.com/
    2020/02/review-cochrane-wont-publish/.
14. Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, et al.
    Comparative efficacy and acceptability of 21 antidepressant drugs for the acute
    treatment of adults with major depressive disorder: a systematic review and
    network meta-analysis. Lancet 2018;391:1357-66.
15. Higgins JPT, Green S (eds.). Cochrane Handbook for Systematic Reviews of
    Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,
    2011. www.cochrane-handbook.org.
16. Gøtzsche PC. Rewarding the companies that cheated the most in antidepressant
    trials. Mad in America 2018; March 7. https://www.madinamerica.com/2018/
    03/rewarding-companies-cheated-most-antidepressant-trials/.
17. Munkholm K, Paludan-Müller AS, Boesen K. Considering the methodological
    limitations in the evidence base of antidepressants for depression: a reanalysis of
    a network meta-analysis. BMJ Open 2019;9:e024886.
18. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be
    crucially important for patients. BMJ 2000;321:585-6.
19. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than
    good? BMJ 2015;350:h2435.
20. Davies J, Read J. A systematic review into the incidence, severity and duration of
    antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav
    2019;97:111-21.
21. Groot P, van Os J. How user knowledge of psychotropic drug withdrawal resulted
    in the development of person-specific tapering medication. Ther Adv
    Psychopharmacol 2020 (paper under review). https://iipdw.org/user-knowledgepsychotropic-drug-withdrawal/.
22. www.survivingantidepressants.org. Surviving Antidepressants is a site for peer
    support, documentation, and education about withdrawal symptoms caused by
    depression pills, with more than 6,000 reports of patient experiences.
23. Inner Compass Initiative: The Withdrawal Project. https://withdrawal.
    theinnercompass.org. Resources for withdrawal from psychiatric drugs.
24. Hall W. Harm reduction guide to coming off psychiatric drugs. The Icarus Project
    and Freedom Center; 2012. www.theicarusproject.net/resources/publications/
    harm-reduction-guide-to-comingoff-psychiatric-drugs-and-withdrawal/.
25. Benzo buddies. Mutual-support environment for those who wish to withdraw from
    benzodiazepines. www.benzobuddies.org.
26. Recovery Road. Antidepressant & Benzodiazepine Withdrawal Support.
    www.recovery-road.org.
27. Ashton CH. Benzodiazepines: how they work and how to withdraw. Newcastle:
    University of Newcastle; 2011. www.benzo.org.uk/manual/.
28. Toft B, Gøtzsche PC. Psykofarmakaepidemien kan bekæmpes. Information 2017;
    Apr 3. https://www.information.dk/debat/2017/04/psykofarmakaepidemien-kanbekaempes.
29. Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself.
    Copenhagen: People’s Press; 2019.
30. McLaren N. Anxiety, the inside story. How biological psychiatry got it wrong.
    Ann Arbor: Future Psychiatry Press; 2018.
31. Christensen DC. Dear Luise: a story of power and powerlessness in Denmark’s
    psy
32. Ostrow L, Jessell L, Hurd M, Darrow SM, Cohen D. Discontinuing psychiatric
    medications: a survey of long-term users. Psychiatr Serv 2017;68:1232-8.
33. Groot P, van Os J. Antidepressant tapering strips to help people come off
    medication more safely. Psychosis 2018;10:142-5.
34. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal
    symptoms. Lancet Psychiatry 2019;6:538-46.
35. Sørensen A, Rüdinger B, Gøtzsche PC, Toft BS. A practical guide to slow
    psychiatric drug withdrawal. Copenhagen 2020; Jan 4. https://www.deadlymedicines.dk/wp-content/uploads/A-practical-guide-to-drug-withdrawal.pdf.
36. Breggin P. Psychiatric drug withdrawal: A guide for prescribers, therapists,
    patients and their families. New York: Springer; 2012.
37. Simons P. Peer-support groups were right, guidelines were wrong: Dr. Mark
    Horowitz on tapering off antidepressants. Mad in America 2019; Mar 20.
    https://www.madinamerica.com/2019/03/peer-support-groups-right-officialguidelines-wrong-dr-mark-horowitz-tapering-off-antidepressants/.
38. Zinkler M, von Peter S. End coercion in mental health services—toward a system
    based on support only. Laws 2019;8:19.
39. Fiorillo A, De Rosa C, Del Vecchio V, Jurjanz L, Schnall K, Onchev G, et al.
    How to improve clinical practice on involuntary hospital admissions of psychiatric patients: suggestions from the EUNOMIA study. European Psychiatry
    2011;26:201-7.
40. Scanlan JN. Interventions to reduce the use of seclusion and restraint in inpatient
    psychiatric settings: what we know so far, a review of the literature. Int J Soc
    Psychiat 2010;56:412–23.
41. Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients’
    rights and the law not respected by Appeals Board in Denmark. Clin Neuropsychiatry 2019;16:229-33.
42. Gøtzsche PC, Sørensen A. Systematic violations of patients’ rights and lack of
    safety: cohort of 30 patients forced to receive antipsychotics. Ind J Med Ethics
    2020. Published online Aug 12. Free access.
43. Dold M, Li C, Tardy M, et al. Benzodiazepines for schizophrenia. Cochrane
    Database Syst Rev 2012;11:CD006391.
44. Frandsen P. Et anker af flamingo: Det, vi glemmer, gemmer vi i hjertet. Odense:
    Mellemgaard; 2019.
45. Breggin P. Brain-disabling treatments in psychiatry: drugs, electroshock and the
    psychopharmaceutical complex. New York: Springer; 2007.
46. What does akathisia and tardive dyskinesia look like? Videos of children and
    adults who have been permanently brain damaged by neuroleptics. Undated.
    https://www.deadlymedicines.dk/lectures/.
47. Moncrieff J. Antipsychotic maintenance treatment: time to rethink? PLoS Med
    2015;12: e1001861.
48. Karon BP. All I know about Peter Breggin. In: The International Center for the
    Study of Psychiatry and Psychology. The Conscience of Psychiatry. The reform
    work of Peter R. Breggin, MD. New York: Lake Edge Press; 2009.
49. Gøtzsche PC. Forced drugging with antipsychotics is against the law: decision in
    Norway. Mad in America 2019; May 4. https://www.madinamerica.com/
    2019/05/forced-drugging-antipsychotics-against-law/.
50. Gottstein J. The Zyprexa papers. Anchorage: Jim Gottstein; 2020.

Chapter 5. Survival kit for young psychiatrists

1. Drachmann H. Klinikchef må ikke længere arbejde som psykiater. Politiken 2013;
   Feb 1.
2. Hildebrandt S. Lars Søndergård mistænkes atter for at overmedicinere. Dagens
   Medicin 2015; Oct 23.
3. Hildebrandt S. ”Det er monstrøse doser af medicin.” Dagens Medicin 2015; Oct 23.
4. Schmidt M. Svar fra ledelsen i Psykiatrien Vest. Dagens Medicin 2015; Oct 23.
5. Hildebrandt S. Derfor er Lars Søndergårds supervisor sat under skærpet tilsyn.
   Dagens Medicin 2016; Mar 3.
6. https://illnessquiz.com/schizotypal-personality-disorder-test/.
7. Mayo Clinic. Schizotypal personality disorder. https://www.mayoclinic.org/diseases-conditions/schizotypal-personality-disorder/symptoms-causes/syc20353919.
8. Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood
   disorders: A systematic review. Int J Risk Saf Med 2019;30:155-66.
9. Svensson P. Så stoppade GU-professor allmänhetens insyn i läkemedelsforskning.
   Göteborgs-posten 2018; Jan 20. http://www.gp.se/nyheter/g%C3%B6teborg/
   s%C3%A5-stoppade-gu-professor-allm%C3%A4nhetens-insyn-i-l%C3%A4kemedelsforskning-1.5069930.
10. Sternbeck P. Brallorna nere på professorn Elias Eriksson. Equal 2018; Jan 16.
11. Riksdagens Ombudsman. Kritik mot Göteborgs universitet for handläggningen av
    en begäran om utlämnande av allmänna handlingar m.m. 2017; Dec 20:Dnr
    7571-2016.
12. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of
    repeated suicide attempts: systematic review. J R Soc Med 2017;110:404-10.
13. Sveriges radio. Striden om de antidepressiva medlen. 2017; Aug 28.
    http://sverigesradio.se/sida/avsnitt/943828?programid=412.
14. Gøtzsche PC. National boards of health are unresponsive to children driven to
    suicide by depression pills. Mad in America 2020; Mar 15. https://www.
    madinamerica.com/2020/03/children-driven-suicide-depression-pills/.
15. Frankfurt HG. On bullshit. New Jersey: Princeton University Press; 2005.
16. Läkemedelsbehandling av depression, ångestsyndrom och tvångssyndrom hos
    barn och vuxna. Läkemedelsverket 2016; Dec 8.
17. Barczyk ZA, Rucklidge JJ, Eggleston M, Mulder RT. Psychotropic medication
    prescription rates and trends for New Zealand children and adolescents 2008-
    2016. J Child Adolesc Psychopharmacol 2020;30:87-96.
18. UNICEF Office of Research. Building the future: children and the sustainable
    development goals in rich countries. Innocenti ReportCard 14; 2017.
19. Hjelmeland H, Jaworski K, Knizek BL, Ian M. Problematic advice from suicide
    prevention experts. Ethical Human Psychology and Psychiatry 2018;20:79-85.
20. Whitaker R, Blumke D. Screening + drug treatment = increase in veteran suicides.
    Mad in America 2019; Nov 10. https://www.madinamerica.com/2019/11/
    screening-drug-treatment-increase-veteran-suicides/.
21. Gøtzsche PC. Deadly medicines and organised crime: How big pharma has
    corrupted health care. London: Radcliffe Publishing; 2013.
22. Videos of talks presented at the inaugural symposium for the Institute for
    Scientific Freedom. 2019; Mar 9.
    https://www.youtube.com/playlist?list=PLoJ5D4KQ1G0Z_ZQo5AIIiuuspAKCn
    c49T.
23. Medawar C, Hardon A. Medicines out of Control? Antidepressants and the
    conspiracy ofgoodwill. Netherlands: Aksant Academic Publishers; 2004.
24. Stordrange IL. The happy pill. She survived 10 years of ”torture” in psychiatry.
    2017. https://www.youtube.com/watch?v=T4kVpNmYzBU&t=1s. Version with
    Norwegian subtitles: https://ingerlenestordrang.wixsite.com/lykkepillen.
25. Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself.
    Copenhagen: People’s Press; 2019.
26. Hoel A. Cause of death: unknown. 2017; Mar 24. https://www.imdb.com/title
    /tt6151226/.
27. Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors
    versus placebo in patients with major depressive disorder. A systematic review
    with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017;17:58.
28. Gøtzsche PC. Antidepressiva skader mere end de gavner. Dagens Medicin 2017;
    Mar 15.
29. Gøtzsche P. The meeting was sponsored by merchants of death. Mad in America
    2014; July 7. http://www.madinamerica.com/2014/07/meeting-sponsored-merchants-death/.
30. Pedersen AT. Diagnosing Psychiatry.
    https://vimeo.com/ondemand/diagnosingpsychiatryen.
31. Pedersen AT. Debat: Vi har ret til at undre os. Journalisten 2017; May 8.
32. Christensen AS. DR2 undersøger Danmark på piller. 2013; Mar 20.
    https://www.dr.dk/presse/dr2-undersoeger-danmark-paa-piller.
33. Ditzel EE. Psykiatri-professor om DR-historier: ”Skræmmekampagne der kan
    koste liv.” Journalisten 2013; Apr 11. https://journalisten.dk/psykiatri-professorom-dr-historier-skraemmekampagne-der-kan-koste-liv/.
34. Gøtzsche PC. Death of a whistleblower and Cochrane’s moral collapse. Copenhagen: People’s Press; 2019.
35. Heilbuth PE. Pillens mørke skygge. DR1 2013; Apr 14.
36. Heilbuth PE. Dårlig presseetik, Politiken. Politiken 2013; Apr 19.
37. Thisted K. Jeg tager lykkepiller, ellers var jeg død! Ekstra Bladet 2015; Oct 24.
38. Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s
    Press; 2015.
39. Spencer M. The Carter Center’s guide for mental health journalism: don’t
    question, follow the script. Mad in America 2020; Feb 23.
    https://www.madinamerica.com/ 2020/02/carter-center-guide-mental-healthjournalism/.
40. Whitaker R. Anatomy of an epidemic, 2nd edition. New York: Broadway Paperbacks; 2015.
41. Gøtzsche PC. Psychiatry gone astray. 2014; Jan 21. https://davidhealy.org/psychiatry-gone-astray/.
42. Gøtzsche PC. Unwarranted criticism of “Psychiatry cone astray.” Mad in America
    2014; Feb 20. https://www.madinamerica.com/2014/02/unwarranted-criticismpsychiatry-gone-astray/.
43. Jorm AF, Korten AE, Jacomb PA, et al. ”Mental health literacy”: a survey of the
    public’s ability to recognise mental disorders and their beliefs about the effecttiveness of treatment. Med J Aus 1997;166:182-6.
44. Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients’
    rights and the law not respected by Appeals Board in Denmark. Clin Neuropsychiatry 2019;16:229-33.
45. Gøtzsche PC, Sørensen A. Systematic violations of patients’ rights and lack of
    safety: cohort of 30 patients forced to receive antipsychotics. Ind J Med Ethics
    2020. Published online Aug 12. Free access.